Table 3.
Risk of primary outcomes for patients on ARB compared with those without ARB.
| Outcomes | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Cardiovascular mortality | 0.31 (0.15, 0.66) | 0.002 | 0.30 (0.14, 0.64) | 0.002 | 0.32 (0.18, 0.90) | 0.004 |
| Non-fatal myocardial infarction | 0.87 (0.53, 1.45) | 0.605 | 0.87 (0.52, 1.44) | 0.576 | 0.89 (0.53, 1.52) | 0.692 |
| Non-fatal stroke | 1.01 (0.38, 2.71) | 0.977 | 1.01 (0.38, 2.72) | 0.977 | 1.04 (0.38, 2.84) | 0.933 |
Model 1: Unadjusted. Model 2: Adjusted for baseline age and gender. Model 3: Added race, education, Body Mass Index (BMI), smoking history, systolic and dilated blood pressure, HbA1c level, lipid level (low-density lipoprotein, high-density lipoprotein and triglyceride), therapies, previous heart failure, previous CVD, sulfonylureas, biguanides, meglitinide, alpha-glucosidase inhibitors, thiazolidinediones, regular insulins and statins to model 2. Abbreviations: ARB, angiotensin receptor blocker; HR, hazard ratio; CI, confidence interval.